Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$132.00K$132.00Kderived+83.3% vs Q4 2024 Net Income-$120.36M-$120.36MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$122,749,000N/M Operating Cash Flowderived-$23,754,000N/M Free Cash Flowderived-$23,994,000N/M Margins · derivedOperating margin-92991.7%+28495.8 pt vs Q4 2024
Net margin-91178.0%+19551.1 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end